Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
Multi-specific antibodies
Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission...
Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...
Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Roche’s Lunsumio Receives NMPA Approval for R/R Follicular Lymphoma Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received marketing approval from...
CStone Pharmaceuticals Initiates First-in-Human Trial for PD-1/VEGF/CTLA-4 Trispecific Antibody CS2009
China-based CStone Pharmaceuticals (HKG: 2616) has announced the clinical filing for its CS2009, a PD-1/VEGF/CTLA-4...
ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Amulirafusp Alfa in NMOSD
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced the commencement of...
Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment
US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell...
Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024
China-based Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced the presentation of results from...
Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting
China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...
Amgen’s Blincyto Meets Primary Endpoint in Phase III AALL1731 Study for Pediatric B-ALL
US-based biotechnology company Amgen (NASDAQ: AMGN) has published the results from the Phase III study...
Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials
Janssen-Cilag International NV, a subsidiary of US healthcare giant Johnson & Johnson (J&J; NYSE: JNJ),...
Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the US Food and Drug Administration...
Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer
Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track...
Merus N.V. Receives FDA Approval for Bizengri for NRG1+ Pancreatic and Lung Cancers
Holland-based Merus N.V. (NASDAQ: MRUS) has announced that it has received FDA approval for its...
Ipsen Secures Global Licensing Agreement for Biomunex Pharmaceuticals’ BMX-502 T Cell Engager
France-based Ipsen (OTCMKTS: IPSEY) has announced a significant global licensing agreement with compatriot firm Biomunex...
OncoC4, Inc. Receives FDA Clearance for AI-081, a PD-1 and VEGF Bispecific Antibody
US-based OncoC4, Inc. has announced that it has received clinical clearance from the US Food...
Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs
Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs)...
Betta Pharmaceuticals’ MCLA-129 Approved for Clinical Trial in Advanced Solid Tumors
China’s Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from...
LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced another licensing deal, signing...